Journal for ImmunoTherapy of Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=581563, encodeId=c21b5815635a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9bf5079740, createdName=young喵喵K, createdTime=Mon Dec 16 00:19:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230194, encodeId=49ab12301945e, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201007/099799ef0ff74292905c59b2424469f9/6f0aff90a8294f3c89413e6d03feb011.jpg, createdBy=8edf2386442, createdName=dnsnns, createdTime=Sat Jul 02 21:58:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189803, encodeId=fa5211898032f, content=BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE Please confirm whether you have completed and uploaded the relevant checklist. 麻烦问一下这个Research checklist怎么搞呢各位大神, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Thu Feb 03 00:19:44 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省)]

2023-06-15 ms4000001058776765 来自北京

为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？

38 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=581563, encodeId=c21b5815635a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9bf5079740, createdName=young喵喵K, createdTime=Mon Dec 16 00:19:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230194, encodeId=49ab12301945e, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201007/099799ef0ff74292905c59b2424469f9/6f0aff90a8294f3c89413e6d03feb011.jpg, createdBy=8edf2386442, createdName=dnsnns, createdTime=Sat Jul 02 21:58:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189803, encodeId=fa5211898032f, content=BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE Please confirm whether you have completed and uploaded the relevant checklist. 麻烦问一下这个Research checklist怎么搞呢各位大神, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Thu Feb 03 00:19:44 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省)]

2019-12-16 young喵喵K

审稿速度:1.0 | 投稿命中率:25.0
经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇

188 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=581563, encodeId=c21b5815635a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9bf5079740, createdName=young喵喵K, createdTime=Mon Dec 16 00:19:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230194, encodeId=49ab12301945e, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201007/099799ef0ff74292905c59b2424469f9/6f0aff90a8294f3c89413e6d03feb011.jpg, createdBy=8edf2386442, createdName=dnsnns, createdTime=Sat Jul 02 21:58:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189803, encodeId=fa5211898032f, content=BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE Please confirm whether you have completed and uploaded the relevant checklist. 麻烦问一下这个Research checklist怎么搞呢各位大神, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Thu Feb 03 00:19:44 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省)]

2022-07-02 dnsnns

偏重的研究方向：肿瘤免疫
经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单

57 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=581563, encodeId=c21b5815635a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9bf5079740, createdName=young喵喵K, createdTime=Mon Dec 16 00:19:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230194, encodeId=49ab12301945e, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201007/099799ef0ff74292905c59b2424469f9/6f0aff90a8294f3c89413e6d03feb011.jpg, createdBy=8edf2386442, createdName=dnsnns, createdTime=Sat Jul 02 21:58:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189803, encodeId=fa5211898032f, content=BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE Please confirm whether you have completed and uploaded the relevant checklist. 麻烦问一下这个Research checklist怎么搞呢各位大神, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Thu Feb 03 00:19:44 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省)]

2023-03-15 ms5000001365142656 来自天津

这个杂志综述好投吗？

53 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=581563, encodeId=c21b5815635a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9bf5079740, createdName=young喵喵K, createdTime=Mon Dec 16 00:19:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230194, encodeId=49ab12301945e, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201007/099799ef0ff74292905c59b2424469f9/6f0aff90a8294f3c89413e6d03feb011.jpg, createdBy=8edf2386442, createdName=dnsnns, createdTime=Sat Jul 02 21:58:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189803, encodeId=fa5211898032f, content=BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE Please confirm whether you have completed and uploaded the relevant checklist. 麻烦问一下这个Research checklist怎么搞呢各位大神, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Thu Feb 03 00:19:44 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省)]

2022-05-20 ms1000001524948647

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：免疫;癌症
经验分享：2月1日投稿；
2月28日开始awaiting reviewers score,中间select了两轮审稿人；
5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation;
3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定；
第二天早上5点收到主编邮件，3个审稿人，小修。

现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！

109 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=581563, encodeId=c21b5815635a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9bf5079740, createdName=young喵喵K, createdTime=Mon Dec 16 00:19:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230194, encodeId=49ab12301945e, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201007/099799ef0ff74292905c59b2424469f9/6f0aff90a8294f3c89413e6d03feb011.jpg, createdBy=8edf2386442, createdName=dnsnns, createdTime=Sat Jul 02 21:58:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189803, encodeId=fa5211898032f, content=BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE Please confirm whether you have completed and uploaded the relevant checklist. 麻烦问一下这个Research checklist怎么搞呢各位大神, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Thu Feb 03 00:19:44 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省)]

2023-06-12 osmataku 来自北京

投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了

35 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=581563, encodeId=c21b5815635a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9bf5079740, createdName=young喵喵K, createdTime=Mon Dec 16 00:19:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230194, encodeId=49ab12301945e, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201007/099799ef0ff74292905c59b2424469f9/6f0aff90a8294f3c89413e6d03feb011.jpg, createdBy=8edf2386442, createdName=dnsnns, createdTime=Sat Jul 02 21:58:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189803, encodeId=fa5211898032f, content=BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE Please confirm whether you have completed and uploaded the relevant checklist. 麻烦问一下这个Research checklist怎么搞呢各位大神, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Thu Feb 03 00:19:44 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省)]

2023-03-05 osmataku 来自北京

刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。

46 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=581563, encodeId=c21b5815635a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9bf5079740, createdName=young喵喵K, createdTime=Mon Dec 16 00:19:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230194, encodeId=49ab12301945e, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201007/099799ef0ff74292905c59b2424469f9/6f0aff90a8294f3c89413e6d03feb011.jpg, createdBy=8edf2386442, createdName=dnsnns, createdTime=Sat Jul 02 21:58:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189803, encodeId=fa5211898032f, content=BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE Please confirm whether you have completed and uploaded the relevant checklist. 麻烦问一下这个Research checklist怎么搞呢各位大神, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Thu Feb 03 00:19:44 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省)]

2022-02-11 124525fem69暂无昵称

Awaiting Recommendation 是under review的意思么
投稿一周迅速变成这个状态是不是内审没通过要凉了

64 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=581563, encodeId=c21b5815635a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9bf5079740, createdName=young喵喵K, createdTime=Mon Dec 16 00:19:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230194, encodeId=49ab12301945e, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201007/099799ef0ff74292905c59b2424469f9/6f0aff90a8294f3c89413e6d03feb011.jpg, createdBy=8edf2386442, createdName=dnsnns, createdTime=Sat Jul 02 21:58:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189803, encodeId=fa5211898032f, content=BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE Please confirm whether you have completed and uploaded the relevant checklist. 麻烦问一下这个Research checklist怎么搞呢各位大神, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Thu Feb 03 00:19:44 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省)]

2022-02-03 124525fem69暂无昵称

BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE

Please confirm whether you have completed and uploaded the relevant checklist.

麻烦问一下这个Research checklist怎么搞呢各位大神

87 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142895, encodeId=efe42142895b8, content=为什么一直保持10分以上，还是中科院二区，还不如BMC medicine吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jun 15 09:34:20 CST 2023, time=2023-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=581563, encodeId=c21b5815635a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：抱着试一试的态度投了一篇综述，一审较快，大约1月左右，最后给的意见是拒稿建议改后重投，现杂志的出版社已由BMC改为BMJ，已重投一月，仍在定审稿人，估计是感恩节圣诞节啥的比较忙。。希望有个好结果，大家一起加油哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9bf5079740, createdName=young喵喵K, createdTime=Mon Dec 16 00:19:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230194, encodeId=49ab12301945e, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志工作量到了就能投，逻辑可以不严密，比NC和CIR简单, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201007/099799ef0ff74292905c59b2424469f9/6f0aff90a8294f3c89413e6d03feb011.jpg, createdBy=8edf2386442, createdName=dnsnns, createdTime=Sat Jul 02 21:58:04 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119822, encodeId=05ea211982212, content=这个杂志综述好投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ec38179859, createdName=ms5000001365142656, createdTime=Wed Mar 15 23:32:00 CST 2023, time=2023-03-15, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1221095, encodeId=459b1221095dd, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：免疫;癌症 经验分享：2月1日投稿； 2月28日开始awaiting reviewers score,中间select了两轮审稿人； 5月初发邮件催了一下状态，没有回复，但几天后变成了awaiting recommendation; 3天后变成awaiting decision，同时收到一封邮件告知很快会有主编决定； 第二天早上5点收到主编邮件，3个审稿人，小修。 现在上海还在封闭，回实验室闭环补实验了，给自己加个油！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a716407737, createdName=ms1000001524948647, createdTime=Fri May 20 08:07:50 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2142473, encodeId=978021424e343, content=投nejm都送审的，投这个jitc居然没通过，随着肿瘤免疫热度提高，今年投稿难度增加不少了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Mon Jun 12 23:21:32 CST 2023, time=2023-06-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117728, encodeId=7a01211e72850, content=刚刚投一篇， 10天收到拒稿邮件，最近开始关注这个杂志，前几年一直是1区，今年是第一次跌落2区，捡漏失败。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sun Mar 05 14:35:01 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1192140, encodeId=cef9119214048, content=Awaiting Recommendation 是under review的意思么 投稿一周迅速变成这个状态是不是内审没通过要凉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Fri Feb 11 02:37:41 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189803, encodeId=fa5211898032f, content=BMJ Journals requires compliance to the relevant research reporting guidelines, such as CONSORT, PRISMA, STROBE, RECORD, MOOSE. STARD, SQUIRE, TRIPOD, CHEERS, or ARRIVE Please confirm whether you have completed and uploaded the relevant checklist. 麻烦问一下这个Research checklist怎么搞呢各位大神, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e1952478585, createdName=124525fem69暂无昵称, createdTime=Thu Feb 03 00:19:44 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180016, encodeId=3f3221800163f, content=Research Reporting Guideline checklist在哪里啊，没有找的呢 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a6a8156000, createdName=ms1000000367938648, createdTime=Mon Jan 08 16:31:56 CST 2024, time=2024-01-08, status=1, ipAttribution=四川省)]

2024-01-08 ms1000000367938648 来自四川省

Research Reporting Guideline checklist在哪里啊，没有找的呢

14 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务